NCT04345406 is a Phase 3 clinical trial of ACEIs in COVID, sponsored by Tanta University.

Who is sponsoring NCT04345406?

NCT04345406 is sponsored by Tanta University.

What drugs are being tested in NCT04345406?

Interventions in NCT04345406: ACEIs, Conventional treatment.

Is NCT04345406 still recruiting?

NCT04345406 is currently not yet recruiting. Last updated 14 April 2020.

Last reviewed 2020-04-14 · How we verify

NCT04345406

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19

Not yet recruiting Phase 3 Last updated 14 April 2020

What this trial tests

Phase 3 trial testing ACEIs in COVID in 60 participants. Not yet recruiting.

Timeline

15 April 2020

Primary endpoint
1 December 2029

1 December 2029

Quick facts

Lead sponsor	Tanta University
Phase	Phase 3
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	15 April 2020
Primary completion	1 December 2029
Estimated completion	1 December 2029
Sites	1 location across Egypt

Drugs / interventions tested

ACEIs — full drug profile →
Conventional treatment — full drug profile →

Conditions studied

COVID — all drugs for COVID →

Sponsor

Tanta University

Who can join

Eligibility, any sex, with COVID. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ACEIs as treatment for COVID19

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S, et al · · 2020 · cited 246× · PMID 32687918 · DOI 10.1016/j.lfs.2020.118102
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease.
Tomasoni D, Italia L, Adamo M, Inciardi RM, et al · · 2020 · cited 181× · PMID 32412156 · DOI 10.1002/ejhf.1871
ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis.
Viana SD, Nunes S, Reis F. · · 2020 · cited 122× · PMID 32683039 · DOI 10.1016/j.arr.2020.101123
Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review.
Mackey K, King VJ, Gurley S, Kiefer M, et al · · 2020 · cited 104× · PMID 32422062 · DOI 10.7326/m20-1515
DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
Valencia I, Peiró C, Lorenzo Ó, Sánchez-Ferrer CF, et al · · 2020 · cited 79× · PMID 32848769 · DOI 10.3389/fphar.2020.01161
Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19.
Li X, Zhang Z, Wang Z, Gutiérrez-Castrellón P, et al · · 2022 · cited 58× · PMID 35697684 · DOI 10.1038/s41392-022-01043-6
Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection.
Labò N, Ohnuki H, Tosato G. · · 2020 · cited 57× · PMID 32629875 · DOI 10.3390/cells9071583

Verify or expand the search:

Other recruiting trials for COVID

Currently open trials in the same condition.

NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting

Other Tanta University trials

Trials by the same sponsor.

NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
NCT06966856 — This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcti · Phase 3 · not yet recruiting
NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
NCT07498998 — Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome · NA · not yet recruiting
NCT07114250 — Comparative Study Between Spinal Anesthesia Versus General Anesthesia in Supine Percutaneous Nephrolithotomy Operation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04345406 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tanta University
Last refreshed: 14 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04345406.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing